Topical rosacea therapy: The importance of vehicles for efficacy, tolerability and compliance

Journal of Drugs in Dermatology

Volumn 10, Issue 6, 2011, Pages 627-633

  Jackson, J Mark ^a   Pelle, Michelle ^b,c  

^a University of Louisville School of Medicine   (United States)

^b MedDerm Associates   (United States)

^c UNIVERSITY OF SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; BETA CYCLODEXTRIN; DOXYCYCLINE; METHYL PARABEN; METRONIDAZOLE; NICOTINAMIDE; PETROLATUM; PROPYL PARABEN; PROPYLENE GLYCOL; SULFACETAMIDE; WATER;

ACNE VULGARIS; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; BURN; CLINICAL TRIAL (TOPIC); CREAM; DERMATITIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG SENSITIZATION; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; EYE SWELLING; GEL; HUMAN; LOTION; PATIENT COMPLIANCE; PHOTOALLERGY; PHOTOTOXICITY; PRURITUS; REVIEW; ROSACEA; SIDE EFFECT; SKIN INFLAMMATION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN PENETRATION; SKIN SENSITIVITY; TOPICAL TREATMENT;

ADMINISTRATION, CUTANEOUS; DERMATOLOGIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MEDICATION ADHERENCE; PHARMACEUTICAL VEHICLES; ROSACEA;

EID: 80053061231     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. National Rosacea Society. What is rosacea? Available at: http://www.rosacea.org/index.php. Accessed April 19, 2010.
2. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341. Quiz 342-344.
3. National Rosacea Society. New survey documents prevalence of burning, stinging and itching: Rosacea review. 2006. Available at: http://www.rosacea. org/rr/2006/winter/article-3.php. Accessed April 27, 2010.
4. Lonne-Rahm SB, Fischer T, Berg M. Stinging and rosacea. Acta Derm Venereol. 1999;79:460-461.
5. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
6. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512. Quiz 513-514.
7. Draelos ZD, Colón LE, Preston N, et al. The cosmetic appearance of facial foundation cosmetics applied after metronidazole gel, 1%. Presented at: 67th Annual Meeting of the American Academy of Dermatology: March 6-10, 2009; San Francisco, CA. Poster 731.
8. Draelos ZD. Assessment of skin barrier function in rosacea patients with a novel 1% metronidazole gel. J Drugs Dermatol. 2005;4:557-562.
9. Otto A, Du Plessis J, Wiechers JW. Formulation effects of topical emulsions on transdermal and dermal delivery. Int J Cosmet Sci. 2009;31:1-19.
10. Meshali M, Abdel-Aleem H, Sakr F, et al. Effect of gel composition and phonophoresis on the transdermal delivery of ibuprofen: In vitro and in vivo evaluation. Pharm Dev Technol. 2011;16(2):93-101. Epub January 25, 2010 Jan 25.
11. Wolters Kluwer. Topical rosacea treatment: 12 months prescription data summary. March 2010.
12. Dow G, Basu S. A novel aqueous metronidazole 1% gel with hydrosolubilizing agents (HSA-3). Cutis. 2006;77(suppl 4):18-26. (Pubitemid 43723534)
13. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(suppl 4):3-11. (Pubitemid 43723532)
14. Wagner N, Berthaud C, Laffet G, Caron JC. Differential penetration of skin by topical metronidazole formulations. Adv Ther. 1998;15:197-205. (Pubitemid 28454899)
15. Beutner KR, Lemke S, Calvarese B. A look at the safety of metronidazole 1% gel: Cumulative irritation, contact sensitization, phototoxicity, and photoallergy potential. Cutis. 2006;77(suppl 4):12-17. (Pubitemid 43723533)
16. MetroGel [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; June 2005.
17. Draelos ZD. The rationale for advancing the formulation of azelaic acid vehicles. Cutis. 2006;77(suppl 2):7-11. (Pubitemid 43434303)
18. Finacea [package insert]. Pine Brook, NJ: Intendis, Inc.; 2007.
19. Draelos ZD. Noxious sensory perceptions in patients with mild to moderate rosacea treated with azelaic acid 15% gel. Cutis. 2004;74:257-260. (Pubitemid 39462893)
20. Abramovits W, Kennedy AJ. Sulfur/sodium sulfacetamide preparations. Skinmed. 2004;3:95-101.
21. Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: Focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004;73(suppl 1):29-33. (Pubitemid 38167894)
22. Del Rosso JQ. Adjunctive skin care in the management of rosacea: Cleansers, moisturizers, and photoprotectants. Cutis. 2005;75(suppl 3):17-21; discussion 33-36.
23. Savic S, Weber C, Tamburic S, Savic M, Müller-Goymann C. Topical vehicles based on natural surfactant/fatty alcohols mixed emulsifier: The influence of two polyols on the colloidal structure and in vitro/in vivo skin performance. J Pharm Sci. 2009;98:2073-2090.
24. Fisher AA. Reactions to popular cosmetic humectants. Part III. Glycerin, propylene glycol, and butylene glycol. Cutis. 1980;26:243-244, 269.
25. Nijhawan RI, Molenda M, Zirwas MJ, Jacob SE. Systemic contact dermatitis. Dermatol Clin. 2009;27:355-364.
26. Funk JO, Maibach HI. Propylene glycol dermatitis: Re-evaluation of an old problem. Contact Dermatitis. 1994;31:236-241. (Pubitemid 24311533)
27. Warshaw EM, Botto NC, Maibach HI, et al. Positive patch-test reactions to propylene glycol: A retrospective cross-sectional analysis from the North American Contact Dermatitis Group, 1996 to 2006. Dermatitis. 2009;20:14-20.
28. Fowler JF Jr, Fowler L, Douglas JL, et al. Skin reactions to pimecrolimus cream 1% in patients allergic to propylene glycol: A double-blind randomized study. Dermatitis. 2007;18:134-139. (Pubitemid 47583217)
29. Niren NM. Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: A review. Cutis. 2006;77(suppl 1):11-16. (Pubitemid 43189144)
30. Maiese K, Chong ZZ, Hou J, Shang YC. The vitamin nicotinamide: Translating nutrition into clinical care. Molecules. 2009;14:3446-3485.
31. Fivenson DP. The mechanisms of action of nicotinamide and zinc in inflammatory skin disease. Cutis. 2006;77(suppl 1):5-10.
32. Draelos ZD. Clinical situations conducive to proactive skin health and anti-aging improvement. J Investig Dermatol Symp Proc. 2008;13:25-27. (Pubitemid 351450902)
33. Levin J, Del Rosso JQ, Momin SB. How much do we really know about our favorite cosmeceutical ingredients? J Clin Aesthet Dermatol. 2010;3:22-41.
34. Draelos ZD, Ertel K, Berge C. Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis. 2005;76:135-141. (Pubitemid 41290900)
35. Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: Past and present. J Pharm Sci. 2007;96:3155-3167.
36. Soni MG, Burdock GA, Taylor SL, Greenberg NA. Safety assessment of propyl paraben: A review of the published literature. Food Chem Toxicol. 2001;39:513-532. (Pubitemid 32429464)
37. Final amended report on the safety assessment of methylparaben, ethylparaben, propylparaben, isopropylparaben, butylparaben, isobutylparaben, and benzylparaben as used in cosmetic products. Int J Toxicol. 2008;27(suppl 4):1-82.
38. Del Rosso JQ, Lehman PA, Raney SG. Impact of order of application of moisturizers on percutaneous absorption kinetics: Evaluation of sequential application of moisturizer lotions and azelaic acid gel 15% using a human skin model. Cutis. 2009;83:119-124.
39. Weber TM, Ceilley RI, Buerger A, et al. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A. J Cosmet Dermatol. 2006;5:227-232. (Pubitemid 44314384)
40. Del Rosso JQ, Baum EW, Draelos ZD, et al. Azelaic acid gel 15%: Clinical versatility in the treatment of rosacea. Cutis. 2006;78(suppl 5):6-19. (Pubitemid 44952086)
41. Colón LE, Johnson LA, Gottschalk RW. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis. 2007;79:317-321.
42. Lebrun CM. Rosac cream with sunscreens (sodium sulfacetamide 10% and sulfur 5%). Skinmed. 2004;3:92.
43. Torok HM, Webster G, Dunlap FE, Egan N, Jarratt M, Stewart D. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis. 2005;75:357-363. (Pubitemid 40905319)
44. Gupta G, Mallefet P, Kress DW, Sergeant A. Adherence to topical dermatological therapy: Lessons from oral drug treatment. Br J Dermatol. 2009;161:221-227.